1
|
Parameswarappa SG, Pereira CL, Seeberger PH. Synthesis of Streptococcus pneumoniae serotype 9V oligosaccharide antigens. Beilstein J Org Chem 2020; 16:1693-1699. [PMID: 32733612 PMCID: PMC7372248 DOI: 10.3762/bjoc.16.140] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 06/18/2020] [Indexed: 01/17/2023] Open
Abstract
Streptococcus pneumoniae (SP) bacteria cause serious invasive diseases. SP bacteria are covered by a capsular polysaccharide (CPS) that is a virulence factor and the basis for SP polysaccharide and glycoconjugate vaccines. The serotype 9V is part of the currently marketed conjugate vaccine and contains an acetate modification. To better understand the importance of glycan modifications in general and acetylation in particular, defined oligosaccharide antigens are needed for serological and immunological studies. Here, we demonstrate a convergent [2 + 3] synthetic strategy to prepare the pentasaccharide repeating unit of 9V with and without an acetate group at the C-6 position of mannosamine.
Collapse
Affiliation(s)
- Sharavathi G Parameswarappa
- Max Planck Institute of Colloids and Interfaces, Biomolecular Systems Department, Am Mühlenberg 1, 14476 Potsdam, Germany.,Vaxxilon Deutschland GmbH, Magnusstraße 11, 12489 Berlin, Germany
| | - Claney L Pereira
- Max Planck Institute of Colloids and Interfaces, Biomolecular Systems Department, Am Mühlenberg 1, 14476 Potsdam, Germany.,Vaxxilon Deutschland GmbH, Magnusstraße 11, 12489 Berlin, Germany
| | - Peter H Seeberger
- Max Planck Institute of Colloids and Interfaces, Biomolecular Systems Department, Am Mühlenberg 1, 14476 Potsdam, Germany.,Freie Universität Berlin, Institute for Chemistry and Biochemistry, Arnimallee 22, 14195 Berlin, Germany
| |
Collapse
|
2
|
Rijkers GT, Pelton SI. The old man's friend. Pneumonia (Nathan) 2018; 10:8. [PMID: 30062083 PMCID: PMC6058374 DOI: 10.1186/s41479-018-0052-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 06/27/2018] [Indexed: 11/17/2022] Open
Affiliation(s)
- Ger T Rijkers
- 1Science Department, University College Roosevelt, P.O. Box 94, 4330 AB Middelburg, The Netherlands
| | - Stephen I Pelton
- 2Boston Medical Center, Boston University Schools of Medicine and Public Health, Boston, USA
| |
Collapse
|
3
|
Rijkers GT, Yousif LI, Spoorenberg SM, van Overveld FJ. Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly. Risk Manag Healthc Policy 2018; 11:55-65. [PMID: 29636634 PMCID: PMC5881283 DOI: 10.2147/rmhp.s130405] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Pneumococcal pneumonia is a serious disease with considerable morbidity and mortality in the elderly. Despite adequate antibiotic treatment, the long-term mortality of pneumococcal pneumonia remains high. Preventive measures in the form of vaccination, therefore, are warranted. Twenty-three-valent polysaccharide vaccines have a broad coverage but limited efficacy. Pneumococcal conjugate vaccines have been shown in children to be able to prevent invasive and mucosal pneumococcal diseases. It should be realized that the serotype composition of current pneumococcal conjugate vaccines is not tailored for the elderly, and that replacement disease can occur. Yet, the current 13-valent conjugate vaccine has been shown to protect against infections with vaccine serotypes. Long-term mortality of pneumococcal pneumonia should be included in policy making about the introduction of these vaccines for the elderly.
Collapse
Affiliation(s)
- Ger T Rijkers
- Department of Science, University College Roosevelt, Middelburg, the Netherlands.,Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, the Netherlands
| | - Laura Ie Yousif
- Department of Science, University College Roosevelt, Middelburg, the Netherlands
| | | | - Frans J van Overveld
- Department of Science, University College Roosevelt, Middelburg, the Netherlands
| |
Collapse
|
4
|
Rijkers GT. Fixing a Hole: Preventing Pneumococcal Pneumonia by Vaccination. Front Immunol 2016; 7:349. [PMID: 27679637 PMCID: PMC5020054 DOI: 10.3389/fimmu.2016.00349] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Accepted: 08/30/2016] [Indexed: 11/13/2022] Open
Affiliation(s)
- Ger T Rijkers
- Science Department, University College Roosevelt, Middelburg, Netherlands; Laboratory for Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, Netherlands
| |
Collapse
|
5
|
Baratali L, Lang PO. [Pneumococcal infections: Appraisal and perspectives in terms of adult vaccination]. Presse Med 2015; 44:1155-61. [PMID: 26363530 DOI: 10.1016/j.lpm.2015.04.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Revised: 04/02/2015] [Accepted: 04/16/2015] [Indexed: 11/26/2022] Open
Abstract
Pneumococcal diseases are the first cause of bacterial infections in adult and in the aged adult. While its considerable morbi-mortality is potentially preventable through vaccination, the interest of anti-pneumococcal vaccination in these populations is still debated. Effectiveness appraisal of current anti-pneumococcal vaccines and the perspectives in terms of preventive strategies against Streptococcus pneumoniae infections in the adult population are presented.
Collapse
Affiliation(s)
- Laila Baratali
- CHUV, service de médecine interne, 46, rue du Bugnon, 1011 Lausanne, Suisse
| | - Pierre Olivier Lang
- CHUV, service de médecine interne, 46, rue du Bugnon, 1011 Lausanne, Suisse; CHUV, service de gériatrie et de réhabilitation gériatrique, Mont Paisible 16 (MP16/04/414), 1011 Lausanne, Suisse; Anglia Ruskin University, Health and wellbeing academy, Cambridge, Royaume-Uni.
| |
Collapse
|
6
|
Safari D, Marradi M, Chiodo F, Th Dekker HA, Shan Y, Adamo R, Oscarson S, Rijkers GT, Lahmann M, Kamerling JP, Penadés S, Snippe H. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. Nanomedicine (Lond) 2012; 7:651-62. [DOI: 10.2217/nnm.11.151] [Citation(s) in RCA: 136] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Aims: Coupling of capsular polysaccharides of pathogens to immunogenic protein carriers (conjugate vaccines) improves carbohydrate immune response. Our idea is to explore gold nanoclusters as carriers to prepare fully synthetic carbohydrate vaccines. Materials & methods: Gold glyconanoparticles bearing a synthetic tetrasaccharide epitope related to the Streptococcus pneumoniae type 14 capsular polysaccharide (Pn14PS), the T-helper ovalbumin 323–339 peptide (OVA323–339), and D-glucose were prepared by a one-pot method. Their immunogenicity was tested in mice. Cytokine levels after spleen cell stimulation with OVA323–339 were analyzed using a luminex-multiplex cytokine assay. The capacity of the evoked antibodies to promote the uptake of S. pneumoniae type 14 by leukocytes was assessed. Results & discussion: Glyconanoparticles containing 45% of tetrasaccharide and 5% OVA323–339 triggered specific anti-Pn14PS IgG antibodies. Cytokine levels confirmed that glyconanoparticles led to T-helper cell activation. The anti-saccharide antibodies promoted the phagocytosis of type 14 bacteria by human leukocytes, indicating the functionality of the antibodies. Conclusion: Gold nanoparticles have great potential as carriers for the development of a great diversity of fully synthetic carbohydrate-based vaccines. Original submitted 17 May 2011; Revised submitted 27 July 2011
Collapse
Affiliation(s)
- Dodi Safari
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Marco Marradi
- Laboratory of GlycoNanotechnology, Biofunctional Nanomaterials Unit, CIC biomaGUNE, San Sebastián, Spain and Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), San Sebastián, Spain
| | - Fabrizio Chiodo
- Laboratory of GlycoNanotechnology, Biofunctional Nanomaterials Unit, CIC biomaGUNE, San Sebastián, Spain
| | - Huberta A Th Dekker
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Yulong Shan
- School of Chemistry, Bangor University, Bangor, UK
| | - Roberto Adamo
- Bijvoet Center, Department of Bio-Organic Chemistry, Utrecht University, Utrecht, The Netherlands
| | - Stefan Oscarson
- Center for Synthesis and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
| | - Ger T Rijkers
- Department of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands
| | | | - Johannis P Kamerling
- Bijvoet Center, Department of Bio-Organic Chemistry, Utrecht University, Utrecht, The Netherlands
| | - Soledad Penadés
- Laboratory of GlycoNanotechnology, Biofunctional Nanomaterials Unit, CIC biomaGUNE, San Sebastián, Spain and Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), San Sebastián, Spain
| | - Harm Snippe
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
7
|
Neto JT, de Araujo GTB, Gagliardi A, Pinho A, Durand L, Fonseca M. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil. HUMAN VACCINES 2011; 7:1037-47. [PMID: 21941088 DOI: 10.4161/hv.7.10.15987] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Vaccination of adults aged 60 years and older against Streptococcus pneumonia is not recommended in Brazil. The 23-valent polysaccharide pneumococcal vaccine (PPV23) is only available for institutionalized persons or with underlying diseases despite the substantial medical and economic burden related to pneumococcal infections in adults over than 59 years. The study aimed at evaluating the cost effectiveness of implementing a large PPV program in this population. This analysis was performed using a static decision tree model. Demographic and epidemiological data were obtained from Brazilian official sources and international literature. Economic data were obtained from a study performed in 2007 in a public and a private hospital located in Sao Paulo. Vaccination was assumed to protect for 5 years with 60% effectiveness against bacteremic pneumococcal pneumonia (BPP) and 21% effectiveness against non bacteremic pneumococcal pneumonia (NBPP). Deterministic and sensitivity analyses were performed. The pneumococcal polysaccharide vaccination saved 5,218 life year gained (LYG). The vaccination program was found to be cost effective in the social security and public health care perspectives with a mean incremental cost-effectiveness ratio of R$10,887 and R$8,281 per LYG respectively. Results were sensitive to the vaccine effectiveness against NBPP, the incidence and case-fatality rate of NBPP. From a societal perspective, PPV23 program for adults 60 and older was found to be cost-saving. Pneumococcal polysaccharide vaccination is clinically and economically favored over the present vaccination strategy, in which persons aged over 59 years in Sao Paulo, have not been vaccinated.
Collapse
|
8
|
Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011; 10:1143-67. [PMID: 21810065 DOI: 10.1586/erv.11.99] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Vaccination is the only public-health measure likely to reduce the burden of pneumococcal diseases. In 2010, a group of European experts reviewed evidence on the burden of pneumococcal disease and the immunogenicity, clinical effectiveness and cost-effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23). They also considered issues affecting the future use of PPV23 and pneumococcal conjugate vaccines in the elderly and adults at high risk of pneumococcal disease. PPV23 covers 80-90% of the serotypes responsible for invasive pneumococcal disease in Europe. Primary vaccination and revaccination with PPV23 are well tolerated, induce robust, long-lasting immune responses in elderly adults and are cost effective. Ensuring protection against pneumococcal disease requires monitoring of the changing epidemiology of pneumococcal serotypes causing invasive pneumococcal disease and improving vaccine coverage. In the future, it will be critically important for pneumococcal vaccination recommendations for elderly adults to be based on comparative evaluations of PPV23 and newer pneumococcal conjugate vaccines with regard to their long-term immunogenicity, clinical effectiveness and cost-effectiveness.
Collapse
|
9
|
Karande S. Update on available vaccines in India: report of the APPA VU 2010: I. Indian J Pediatr 2011; 78:845-53. [PMID: 21373831 DOI: 10.1007/s12098-011-0384-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2011] [Accepted: 02/02/2011] [Indexed: 11/25/2022]
Abstract
The Asia Pacific Pediatric Association Vaccinology Update 2010 was held in Mumbai on November 13-14, 2010 to discuss the latest information on burden of infectious diseases, recent developments in vaccines and their impact on immunization practices against infectious diseases occurring in Indian children. During the conference the importance of including conjugate Haemophilus influenzae type b vaccine and anti-rabies vaccines in routine immunization was stressed. Also, the need for giving a second dose of measles mumps rubella vaccine at school entry; and the need for a two-dose varicella vaccine regimen (first dose at 12-15 months of age and a second dose at age 4-6 years) was elucidated. Information related to vaccines which have become available in India in recent years, namely, inactivated poliovirus vaccine; diphtheria, tetanus, acellular pertussis (DTaP) vaccine; conjugate pneumococcal vaccine; rotavirus vaccines; H1N1 vaccines; live attenuated hepatitis A virus vaccine; oral cholera vaccine; tetanus, reduced-dose diphtheria, acellular pertussis (Tdap) vaccine; and human papillomavirus vaccines were discussed.
Collapse
Affiliation(s)
- Sunil Karande
- Department of Pediatrics, Seth Gordhandas Sunderdas Medical College & King Edward VII Memorial Hospital, Parel, Mumbai 400012, India.
| |
Collapse
|